Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/123433
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Predicting Alzheimer disease with β-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing
Other Titles: Predicting Alzheimer disease with beta-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing
Author: Rowe, C.
Bourgeat, P.
Ellis, K.
Brown, B.
Lim, Y.
Mulligan, R.
Jones, G.
Maruff, P.
Woodward, M.
Price, R.
Robins, P.
Tochon-Danguy, H.
O'Keefe, G.
Pike, K.
Yates, P.
Szoeke, C.
Salvado, O.
Macaulay, S.
O'Meara, T.
Head, R.
et al.
Citation: Annals of Neurology, 2013; 74(6):905-913
Publisher: Wiley
Issue Date: 2013
ISSN: 0364-5134
1531-8249
Statement of
Responsibility: 
Christopher C. Rowe, Pierrick Bourgeat, Kathryn A. Ellis, Belinda Brown, Yen Ying Lim, Rachel Mulligan, Gareth Jones, Paul Maruff, Michael Woodward, Roger Price, Peter Robins, Henri Tochon-Danguy, Graeme O’Keefe, Kerryn E. Pike, Paul Yates, Cassandra Szoeke, Olivier Salvado, S. Lance Macaulay, Timothy O’Meara, Richard Head, Lynne Cobiac, Greg Savage, Ralph Martins, Colin L. Masters, David Ames, and Victor L. Villemagne
Abstract: Objective: Biomarkers for Alzheimer disease (AD) can detect the disease pathology in asymptomatic subjects and individuals with mild cognitive impairment (MCI), but their cognitive prognosis remains uncertain. We aimed to determine the prognostic value of β-amyloid imaging, alone and in combination with memory performance, hippocampal atrophy, and apolipoprotein E ε4 status in nondemented, older individuals. Methods: A total of 183 healthy individuals (age = 72.0 ± 7.26 years) and 87 participants with MCI (age = 73.7 ± 8.27) in the Australian Imaging, Biomarkers, and Lifestyle study of ageing were studied. Clinical reclassification was performed after 3 years, blind to biomarker findings. β-Amyloid imaging was considered positive if the (11) C-Pittsburgh compound B cortical to reference ratio was ≥1.5. Results: Thirteen percent of healthy persons progressed (15 to MCI, 8 to dementia), and 59% of the MCI cohort progressed to probable AD. Multivariate analysis showed β-amyloid imaging as the single variable most strongly associated with progression. Of combinations, subtle memory impairment (Z score = -0.5 to -1.5) with a positive amyloid scan was most strongly associated with progression in healthy individuals (odds ratio [OR] = 16, 95% confidence interval [CI] = 3.7-68; positive predictive value [PPV] = 50%, 95% CI = 19-81; negative predictive value [NPV] = 94%, 95% CI = 88-98). Almost all amnestic MCI subjects (Z score ≤ -1.5) with a positive amyloid scan developed AD (OR = ∞; PPV = 86%, 95% CI = 72-95; NPV = 100%, 95% CI = 80-100). Hippocampal atrophy and ε4 status did not add further predictive value. Interpretations: Subtle memory impairment with a positive β-amyloid scan identifies healthy individuals at high risk for MCI or AD. Clearly amnestic patients with a positive amyloid scan have prodromal AD and a poor prognosis for dementia within 3 years.
Keywords: Alzheimer Disease
Rights: © 2014 The Authors. Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
DOI: 10.1002/ana.24040
Grant ID: http://purl.org/au-research/grants/nhmrc/1011689
Appears in Collections:Aurora harvest 4
Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_123433.pdfPublished Version157.22 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.